Safety Profile of Sequential Transcatheter Chemoembolization with DC Bead: Results of 237 Hepatocellular Carcinoma (HCC) Patients

Abstract

Introduction

Complications of chemoembolization performed with DC Bead loaded with doxorubicin (DEBDOX) of diameters 100–300 μm and 300–500 μm are presented in this paper. These diameters are currently the smallest available in drug-eluting technology.

Methods

Included are 237 patients who were treated with sequential DEBDOX with doxorubicin loaded at 37.5 mg/ml of DC Bead. The National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0) were used to categorize complications.

Results

Thirty-day mortality was 1.26% (3/237). Incidence of grade 5 complications was 1.26% (3/237). Overall, grade 4 complications resulted in 5.48% (13/237) (irreversible liver failure, cholecystitis). Grade 2 liver function deterioration developed in 10 patients (4.2%). Cholecystitis/grade 2 and 4 incidents were observed in 3.6–5.06% across sessions (overall 13 patients; 5.48%). Postembolization Syndrome (PES) grade 1 or 2 was observed in up to 86.5%; however, grade 2 was observed in 25–42.19% across treatments. Pleural effusion was seen in eight patients (overall 3.37%; grade 1 in 1.8–3.7% across treatments; grade 3 in 0.42%). Grade 1 procedure-related laboratory pancreatitis was seen in 0.45%, and grade 2 gastrointestinal bleeding was seen in 0.84%. Procedure-associated skin erythema/grade 1 was seen in 0.84%. There was no correlation of liver failure or transient liver function deterioration with the diameter of the beads (p = 0.25–0.37 and p = 0.14–0.89, respectively). Stratifying with the diameter of the beads correlation values was: for cholecystitis (p = 0.11–0.96 across treatments), PES (p = 0.35–0.83), temporary/grade 1 elevation of liver enzymes (p = 0.002–0.0001), and bilirubin (p = 0.04–0.99).

Conclusions

DEBDOX chemoembolization is safe and small calibres do not result in increased complication rates compared with results of series using larger diameters of beads.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Llovet JM, Real MI, Montana X et al (2002) Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739

    PubMed  Article  Google Scholar 

  3. 3.

    Cammà C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224(1):47–54

    PubMed  Article  Google Scholar 

  4. 4.

    Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3):474–481

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Poon RN, Tso WK, Pang RWC et al (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5:1100–1108

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Malagari K, Chatzimichael K, Alexopoulou E et al (2008) Transarterial chemoembolisation of unresectable hepatocellular carcinoma (HCC) with drug eluting beads (DEB); results of an open label study of 62 patients. Cardiovasc Intervent Radiol 31:269–280

    PubMed  Article  Google Scholar 

  7. 7.

    Malagari K, Alexopoulou E, Chatzimichail K et al (2008) Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC Bead. Abdom Imaging 33(5):512–519

    PubMed  Article  Google Scholar 

  8. 8.

    Kettenbach J, Stadler A, Katzler I et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31:468–476

    PubMed  Article  Google Scholar 

  9. 9.

    Malagari K, Pomoni M, Kelekis A et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33(3):541–551

    PubMed  Article  Google Scholar 

  10. 10.

    Lammer J, Malagari K, Vogl T et al (2010) PRECISION V Investigators Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52

    PubMed  Article  Google Scholar 

  11. 11.

    National Cancer Institute (2003) Common terminology criteria for adverse events, version 3.0. National Cancer Institute, Bethesda, MD

    Google Scholar 

  12. 12.

    Common Terminology Criteria for Adverse Events (CTCAE) v3.0, Publish Date: June 10, 2003, Notice of Modifications (March 31, 2003–June 10, 2003)

  13. 13.

    Vogl TJ, Lee C, Lencioni R et al (2010) Liver, gastrointestinal and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial ECR 2010-B241, p 311

  14. 14.

    Kim W, Clark TW, Baum RA et al (2001) Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 12:965–968

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Del Poggio P, Maddeo A, Zabbialini G et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads. J Hepatol 47:157–159

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Song SY, Chung J, Han KW et al (2001) Liver abscess after transcatheter oily chemoembolization for hepatic tumors: Incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 12(3):313–320

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Poon RT, Ngan H, Lo CM et al (2000) Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 73:109–114

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    de Baere T, Roche A, Amenabar JM et al (1996) Liver abscess formation after local treatment of liver tumors. Hepatology 23:1436–1440

    PubMed  Article  Google Scholar 

  19. 19.

    Tarazov PG, Polysalov VN, Prozorovskij KV et al (2000) Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol 41:156–160

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Chan AO, Yuen MF, Hui CK et al (2002) A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94:1747–1752

    PubMed  Article  Google Scholar 

  21. 21.

    Groupe d’Étude et de Traitment du Carcinome Hépatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261

    Article  Google Scholar 

  22. 22.

    Chung JW, Park JH, Han JK et al (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198:33–40

    PubMed  CAS  Google Scholar 

  23. 23.

    Chang JM, Tzeng WS, Pan HB et al (1994) Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 74:2449–2453

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Katsushima S, Inokuma T, Oi H et al (1997) Acute hepatic failure following transcatheter arterial embolization for the treatment of hepatocellular carcinoma. Digestion 58(2):189–195

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Jeon SH, Park KS, Kim YH et al (2007) Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma. Korean J Gastroenterol 50(3):176–182

    PubMed  Google Scholar 

  26. 26.

    Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25

    PubMed  Article  Google Scholar 

  27. 27.

    Lewis AL, Taylor RR, Hall B et al (2006) Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 17(8):1335–1343

    PubMed  Article  Google Scholar 

  28. 28.

    Li X, Feng GS, Zheng CS et al (2003) Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and vasic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol 9:2445–2449

    PubMed  CAS  Google Scholar 

  29. 29.

    Pelletier G, Ducreux M, Gay F et al (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 29:129–134

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Chen MS, Li J-Q, Zhang Y-Q et al (2002) High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 8(1):74–78

    PubMed  Google Scholar 

  31. 31.

    Bronowicki JP, Vetter D, Dumas F et al (1994) Transcatheter oily chemoembolization for hepatocellular carcinoma: a 4-year study of 127 French patients. Cancer 74:16–24

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Stefanini GF, Amorati P, Biselli M et al (1995) Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 75:2427–2434

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Takenaka K, Yoshida K, Nishizaki T et al (1995) Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg 169:400–404

    PubMed  Article  CAS  Google Scholar 

  34. 34.

    Paye F, Farges O, Dahmane M et al (1999) Cytolysis following chemoembolization for hepatocellular carcinoma. Br J Surg 86:176–180

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Wigmore SJ, Redhead DN, Thomson BN et al (2003) Postchemoembolisation syndrome: tumour necrosis or hepatocyte injury? Br J Cancer 89:1423–1427

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Sakamoto I, Aso N, Nagaoki K et al (1998) Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 18(3):605–619

    PubMed  CAS  Google Scholar 

  37. 37.

    Nakamura H, Kondoh H (1986) Emphysematous cholecystitis: complication of hepatic arterial embolization. Cardiovasc Intervent Radiol 9:152–153

    PubMed  Article  CAS  Google Scholar 

  38. 38.

    Kim HK, Chung YH, Song BC et al (2001) Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 32:423–427

    PubMed  Article  CAS  Google Scholar 

  39. 39.

    Wang MQ, Shao RH, Ye HY et al (2005) Investigation of bile duct injury after transcatheter arterial chemoembolization. Zhonghua Zhong Liu Za Zhi 27:609–612

    PubMed  Google Scholar 

  40. 40.

    Leung TK, Lee CM, Chen HC (2005) Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases. World J Gastroenterol 11:1554–1557

    PubMed  Google Scholar 

  41. 41.

    Brennan DDB, Farrelly CB, Cooney RB et al (2005) Abdominal rash after transarterial chemoembolization via the right inferior phrenic artery. J Vasc Interv Radiol 16(9):1269

    PubMed  Google Scholar 

  42. 42.

    Arora BR, Soulen BMC, Haskal ZJ (1999) Cutaneous complications of hepatic chemoembolization via extrahepatic collaterals. J Vasc Interv Radiol 10:1351–1356

    PubMed  Article  CAS  Google Scholar 

  43. 43.

    Brown KT (2004) Fatal pulmonary complications after arterial embolization with 40- to 120-micro m tris-acryl gelatine microspheres. J Vasc Interv Radiol 15(21):197–200

    PubMed  Google Scholar 

  44. 44.

    Maluccio MA, Covey AM, Ben Porat L et al (2008) Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 19(6):862–869

    PubMed  Article  Google Scholar 

  45. 45.

    Liu CL, Ngan H, Lo CM et al (1998) Ruptured hepatocellular carcinoma as a complication of transarterial oily chemoembolization. Br J Surg 85:512–514

    PubMed  Article  CAS  Google Scholar 

  46. 46.

    Battula N, Madanur M, Priest O et al (2009) Spontaneous rupture of hepatocellular carcinoma: a Western experience. Am J Surg 197(2):164–167

    PubMed  Article  Google Scholar 

  47. 47.

    Shin SW, Do YS, Choo SW et al (2006) Diaphragmatic weakness after transcatheter arterial chemoembolization of inferior phrenic artery for treatment of hepatocellular carcinoma. Radiology 241(2):581–583

    PubMed  Article  Google Scholar 

Download references

Conflict of interest

The authors claim no conflict of interest.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Katerina Malagari.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Malagari, K., Pomoni, M., Spyridopoulos, T.N. et al. Safety Profile of Sequential Transcatheter Chemoembolization with DC Bead: Results of 237 Hepatocellular Carcinoma (HCC) Patients. Cardiovasc Intervent Radiol 34, 774–785 (2011). https://doi.org/10.1007/s00270-010-0044-3

Download citation

Keywords

  • Interventional oncology
  • Endovascular treatment
  • Liver/hepatic